Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 32Breast Neoplasms 19Head and Neck Neoplasms 16Neoplasms 11Glioblastoma 8Adenocarcinoma of Lung 8Squamous Cell Carcinoma of Head and Neck 7Colorectal Neoplasms 7Brain Neoplasms 7Adenocarcinoma, Bronchiolo-Alveolar 7Prostatic Neoplasms 6Neoplasm Metastasis 6Gliosarcoma 6Rectal Neoplasms 5Ovarian Neoplasms 5Colonic Neoplasms 5Esophageal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Respiratory Tract Diseases 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

Radiotherapy 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Non-Metastatic Prostate Cancer × Gefitinib × Clear all
NCT00239291 2009-04-23

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

AstraZeneca

Phase 1/2 Completed
42 enrolled
Genitourinary

Non-Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡